Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes – a living clinical practice guideline (2025) Arnav Agarwal

Description

A living clinical practice guideline providing risk-stratified recommendations on the benefits and harms of therapeutics (including SGLT-2 inhibitors, GLP-1 receptor agonists, finerenone, and tirzepatide) for adults with type 2 diabetes, focusing on cardiovascular, kidney, and weight-related outcomes and complications.